MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
OTCMQB
0.091
-0.024
-20.87%
Closed 11:44 11/18 EST
OPEN
0.093
PREV CLOSE
0.115
HIGH
0.105
LOW
0.091
VOLUME
53
TURNOVER
5
52 WEEK HIGH
68.00
52 WEEK LOW
0.034
MARKET CAP
11.21M
P/E (TTM)
-0.3731
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HEPA last week (1109-1113)?
Weekly Report · 2d ago
Weekly Report: what happened at HEPA last week (1102-1106)?
Weekly Report · 11/09 09:03
Weekly Report: what happened at HEPA last week (1026-1030)?
Weekly Report · 11/02 09:03
Hepion Pharmaceuticals receives FDA feedback for GV104
TipRanks · 10/26 12:20
Weekly Report: what happened at HEPA last week (1019-1023)?
Weekly Report · 10/26 09:03
Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
Barchart · 10/26 07:01
Hepion Pharmaceuticals receives positive FDA response on GV104
TipRanks · 10/19 12:26
Weekly Report: what happened at HEPA last week (1012-1016)?
Weekly Report · 10/19 09:03
More
About HEPA
Hepion Pharmaceuticals, Inc. is a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases. Through its subsidiary Gravitas Life Sciences, LLC, a clinical-stage biotechnology company, it is advancing therapeutic candidates in immunology and inflammation, including a transmucosal buccal film of an established opioid antagonist and an oral formulation of a validated anti-inflammatory antibody. Its diagnostic program is built on circulating tumor RNA technology, which reads actively expressed tumor transcripts for the early detection of hepatocellular carcinoma in high-risk cirrhotic patients, a cancer that is curable when found early. Its two licensed programs include GV104 and GV023. GV104 is a transmucosal buccal film of an approved opioid antagonist in clinical development for the temporary prophylaxis of respiratory and/or central nervous system depression. GV023 is an oral formulation of infliximab.

Webull offers Hepion Pharmaceuticals Inc stock information, including OTCMQB: HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.